Reported cellular responses span metabolism and clonogenic growth. Acadesine at 1 mM for 48 h reduced XTT metabolism in CML models, including imatinib-resistant cells, without activating caspase-3 in K562 cells. It also suppressed 10-day CML colony formation. In 3T3-L1 adipocytes, 1 mM AICAR for 24 h inhibited insulin-stimulated glucose uptake by 62 ± 3% (mean ± SEM; n = 11), while basal uptake and GLUT4/HK2 abundance were unchanged. These are model-specific experimental exposures, not recommended working concentrations. [2,3]
AMPK γ2-dependent activation in HEK293 cells
Cell-based study · Isogenic HEK293 cells stably expressing FLAG-tagged wild-type AMPK γ2 or AMP-insensitive γ2 R531G (RG). [1]
AICAR activated AMPK in WT cells but not RG cells. At 3 mM it increased AMPK Thr-172 phosphorylation in WT cells, without a significant rise in ADP:ATP ratio or inhibition of basal oxygen uptake.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3 mM for phosphorylation, nucleotide and oxygen-uptake experiments; Figure 2D also shows a concentration-response series extending to 10 mM.
- Exposure duration
- 1 h
- Method
- Cell incubation followed by immunoprecipitation/kinase assay, immunoblotting, capillary electrophoresis or extracellular flux measurement.
- Co-treatment
- None for the AICAR response; subsequent DNP challenge in oxygen-uptake assay is a separate assay step.
- Reported limits
- AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations
Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: AICAR
Literature evidence for acadesine; no Adooq product-use or batch-validation claim.
Results, AICAR response in WT/R531G cells; Figures 2D, 4, 5A, 6A; Experimental Procedures: AMPK assays, nucleotide analysis, oxygen uptake
AMPK activity after cellular AICAR exposure: Anti-FLAG immunoprecipitation; AMARA peptide substrate; activity assayed with 200 µM AMP; mean ± SD, n = 2. — Figure 2D; AMPK Assays
AMPK Thr-172 phosphorylation: Immunoblotting after 3 mM AICAR for 1 h; duplicate incubations. — Figure 4, AICAR panel and legend
Cellular ADP:ATP ratio and oxygen uptake: Capillary electrophoresis: mean ± SD, n = 2 treated, n = 16 controls; oxygen uptake: Seahorse XF24, mean ± SEM, n = 4–10 (AICAR-specific n not separately given). — Figure 5A and legend; Figure 6A and legend
Reduced CML-cell metabolism without caspase-3 activation
Cell-based study · K562, imatinib-resistant K562 (Ima-R), JURL-MK1, LAMA-84 and Ba/F3 cells expressing WT or T315I BCR-ABL. [2]
Acadesine reduced XTT metabolism in the tested CML and Ba/F3 models, including imatinib-resistant cells. In K562 cells, the effect was not rescued by z-VAD-fmk and was not accompanied by caspase-3 activation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 mM across the cell-line panel and mechanistic comparisons; Figure 1A additionally tests increasing concentrations through 5 mM in K562.
- Exposure duration
- 48 h
- Method
- Incubation at 37°C; XTT absorbance at 490 nm; caspase-3 substrate hydrolysis.
- Co-treatment
- K562 comparison: acadesine 1 mM or imatinib 1 µM, each with or without z-VAD-fmk 50 µM; imatinib is a comparator, not an acadesine combination.
- Reported limits
- AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations
Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: Acadesine
Literature evidence for acadesine; no Adooq product-use or batch-validation claim.
Results: Acadesine-Mediated Inhibition of Cell Viability Does Not Involve Apoptosis; Figure 1A–D; Methods: Cell Lines, Measurement of Cell Metabolism, Caspase 3 Activity
Metabolic activity relative to untreated cells: XTT assay; four determinations in quadruplicate described in Figure 1A. No numerical IC50 or graph-derived percentage adopted. — Figure 1A,B and legend
z-VAD-fmk rescue and caspase-3 activation: XTT and Ac-DEVD-AMC hydrolysis; caspase assay uses Ac-DEVD-CHO to establish specificity; four independent experiments in quadruplicate for Figure 1D. — Figure 1C,D and legend
AMPK knockdown does not rescue the K562 metabolic response
Cell-based study · K562 cells with AMPK shRNA versus empty vector, or combined AMPKα1/α2 siRNAs versus control siRNA. [2]
Acadesine increased AMPK phosphorylation, but reducing AMPK expression with either shRNA or siRNAs did not prevent the reduction in XTT metabolism.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 mM
- Exposure duration
- 48 h of acadesine treatment after 48 h transfection; phosphorylation time course at 2, 6, 24 and 48 h.
- Method
- Electroporation for shRNA or RNAiMAX for siRNA; immunoblotting and XTT assay.
- Co-treatment
- Genetic perturbation of AMPK; imatinib 1 µM is a separate comparator in the siRNA experiment.
- Reported limits
- AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations
Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: Acadesine
Literature evidence for acadesine; no Adooq product-use or batch-validation claim.
Methods: Sh-RNA Assays and si-RNA Assays; Results: AMPK pathway; Figure 4A–E and legend
Rescue of acadesine-induced XTT reduction after AMPK depletion: Expression depletion checked by immunoblot; metabolism measured by XTT. — Figure 4B–E; shRNA/siRNA methods
AMPK and S6 ribosomal-protein phosphorylation: Immunoblot time course following 1 mM acadesine. — Figure 4A and legend
Suppression of CML colony formation
Cell-based study · K562 cells (0.5×10³ cells/mL in Figure 6A) and purified CD34+ cells from one CML patient (10³ cells/mL). [2]
Acadesine inhibited K562 colony formation across 0.25–2.5 mM. In the single patient-derived CD34+ sample, no colonies were detected at 1 mM after 10 days.
Literature-Reported Treatment Conditions
- Treatment concentration
- K562: 0.25, 0.5, 1 and 2.5 mM; patient CD34+ cells: 0.25, 0.5 and 1 mM.
- Exposure duration
- 10 days
- Method
- Semisolid methylcellulose culture; colonies stained with MTT 1 mg/mL and counted with ImageJ.
- Co-treatment
- Imatinib 1 µM is a separate comparator in the patient CD34+ experiment.
- Reported limits
- AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations
Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: Acadesine
Literature evidence for acadesine; no Adooq product-use or batch-validation claim.
Methods: Colony Formation Assay and Primary Cells Isolation; Figure 6A,B and legend; Results: Acadesine Inhibits Tumor Formation
K562 colony formation: Colony counts after 10 days; three determinations in triplicate. — Figure 6A and Results paragraph
Patient CD34+ colony formation: One patient-derived sample; 10-day colony assay. — Figure 6B and Results paragraph
Reduced insulin-stimulated glucose uptake in adipocytes
Cell-based study · Differentiated mouse 3T3-L1 adipocytes. [3]
AICAR inhibited insulin-stimulated glucose uptake without changing basal uptake or GLUT4/HK2 protein abundance. The direct AMPK activator 991 increased ACC phosphorylation but did not reproduce the uptake effect. Adenosine-kinase inhibition with 5-iodotubercidin attenuated the AICAR effect.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 mM for principal comparisons; 0, 0.5, 1 and 2 mM in the concentration-response experiment.
- Exposure duration
- 24 h pretreatment; insulin stimulation 100 nM for 15 min; radiotracer uptake measured over 3 min.
- Method
- [³H]2-deoxyglucose uptake and immunoblotting; 3T3-L1 cells used 8–12 days after differentiation.
- Co-treatment
- Insulin challenge ±100 nM; 991 5 µM is a separate comparator; 5-iodotubercidin 0.1 µM ± AICAR for 24 h in the retained adenosine-kinase inhibitor arm.
- Reported limits
- AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations
Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: AICAR
Literature evidence for acadesine; no Adooq product-use or batch-validation claim.
Methods 2.1, 2.3–2.6, 2.9; Results 3.1, 3.5; Figures 1, 2 and 6a,c–e and legends
Inhibition of insulin-stimulated [³H]2-deoxyglucose uptake by 1 mM AICAR: Radiotracer uptake; mean ± SEM; n = 11 independent experiments. — Results 3.1; Figure 1c and legend; Methods 2.6, 2.9
Basal uptake, GLUT4/HK2 abundance and 991 comparator response: GLUT4/HK2 immunoblots n = 3; 991 uptake n = 3; mean ± SEM. — Figures 1c,d, 2 and legends; Results 3.1
Effect of 5-iodotubercidin on AICAR-mediated uptake inhibition: 5-iodotubercidin 0.1 µM; uptake n = 5 independent experiments, mean ± SEM; no exact rescue percentage inferred. — Results 3.5; Figure 6a,c–e and legend